AEON Biopharma (AEON) Proxy Filing summary

Executive summary

• Special Meeting scheduled for January 21, 2026, to approve key financing, note exchange, and equity plan proposals critical for funding biosimilar development efforts.

• Company is pursuing a Section 351(k) biosimilar regulatory pathway for ABP-450, targeting the therapeutic botulinum toxin market.

• Recent financial results show ongoing operating losses, negative cash flows, and substantial doubt about the ability to continue as a going concern without additional funding.

• Recent public offering and private placement (PIPE) transactions are expected to provide short-term liquidity, but further capital will be needed.

Voting matters and shareholder proposals

• Four proposals to be voted: PIPE Financing Proposal, Exchange Proposal, Equity Plan Proposal, and Adjournment Proposal.

• PIPE Financing Proposal: Issuance and sale of 4,616,924 shares or pre-funded warrants, warrants for 6,581,829 shares, and True-Up Warrants.

• Exchange Proposal: Exchange of $15M convertible notes for equity, a new $1.5M note, and 8M warrants to Daewoong.

• Equity Plan Proposal: Increase shares authorized under the 2023 Incentive Award Plan by 17,288,059 shares and extend plan features.

• Adjournment Proposal: Allows meeting adjournment to solicit more proxies if needed.

• Board recommends voting FOR all proposals.

Board of directors and corporate governance

• Board composition includes a Daewoong designee as part of the Exchange Agreement.

• Board and management recommend all proposals and oversee compliance with NYSE American rules.

• Board has adopted a clawback policy for executive compensation.